InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CETCompany also expects to publish third quarter 2025 financial results on the same day pre-market JENA, Germany, Nov. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical trial of oral C5aR inhibitor INF904 i ...